Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year. Read more about how Biologics and Biosimilars help fight chronic disease as well as the difference between Generics and Biosimilars.
Related Posts
The Consequences of Underrepresentation in Clinical Trial Design
Image credit: Pixel-Shot | stock.adobe.com Clinical trials are opportunities to advance how we diagnose, treat, and prevent disease, as well…
Emmes’ Peter Ronco on Small Biopharma & Clinical Trial Partnerships
ACT: Today, you were a part of the Choosing the Right Allies: Ensuring Clinical Trial Success for Small Biopharma session.…
Placebos, Politics, and the Ethics of Vaccine Trials
This is the Applied Clinical Trials Brief—your fast track to the latest insights in clinical research operations. In under three…
